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Introduction 
Presently, two vascular endothelial growth factor (VEGF) inhibi-
tors are widely used for the treatment of  neovascular age-related 
macular degeneration (ARMD): bevacizumab (Avastin; Genen-
tech, South San Francisco, CA) and ranibizumab (Lucentis; Ge-
nentech, South San Francisco, CA). Both bevacizumab and ranibi-
zumab are derived from the same murine monoclonal antibody 
against VEGF-A and bind to the same site of  VEGF-A, thereby 
neautralizing all known biologically active forms of  VEGF.[1,2]
Bevacizumab is a recombinant humanized monoclonal antibody 
that was the first anti-VEGF drug to be approved in 2004 by 
the Food and Drug Administration (FDA) for the intravenous 
treatment of  metastatic colorectal cancer.[1] A  study in which 
bevacizumab was used intravenously for the treatment of  neovas-
cular ARMD reported promising optical coherence tomography 
(OCT) and visual acuity results.[3] The first report of  intravit-
real bevacizumab (IVB) administration for neovascular ARMD 
was published in 2005.[4] Encouraging results for its efficacy and 
safety, and its low cost and worldwide availability made it a popu-
lar choice for the treatment of  many ocular disorders, including 
neovascular ARMD.
Ranibizumab is a recombinant humanized antibody fragment 
that binds and inhibits the action of  VEGF-A. Ranibizumab was 
approved for the treatment of  neovascular ARMD by the FDA 
in 2006 after Phase III randomized and controlled clinical trials, 
known as MARINA and ANCHOR, proved its safety and effi-
cacy.[5,6]
Once ranibizumab became an on-label drug, many medicare pa-
tients who were undergoing treament with bevacizumab were 
switched to ranibizumab. In this study, the outcomes of  patients 
transitioned from bevacizumab to ranibizumab for the treatment 
of  neovascular ARMD were evaluated.
Abstract
Purpose: To compare the outcomes after switching from intravitreal bevacizumab (IVB) to intravitreal ranibizumab (IVR) in patients 
with neovascular age related macular degeneration (ARMD).
Material and Methods:  A retrospective review of  patients with neovascular ARMD, who were switched from treatment with Pro Re 
Nata (PRN) IVB to PRN IVR, was conducted in a university clinic. IVB (1.25 mg/0.05 ml) and IVR (0.5 mg/0.05 ml) were used. Re-
treatment criteria were defined based on an activity scoring (AS) system developed in our clinic. An AS was calculated for each lesion at 
each visit. AS results and the number of  injections before and after switching treatment to IVR were compared.
Results: 32 eyes of  31 patients with neovascular ARMD were included in the study. The mean follow-up period was 12.3±4.7 months. 
The mean duration of  IVB treatment was 8.1±3.1 months followed by 4.2±1.6 months with IVR. At the beginning of  the study the mean 
AS was 8.9, (Visual Acuity) VA : 0.99 logMAR, and Central Foveal Thickness (CFT): 312.7±81.1µ. A month after the last IVB injection, 
AS became 5.1, VA: 0.69 logMAR, and CFT: 210.4±80.4µ (p<0.05). Likewise, a month after the last IVR injection, AS, VA and CFT 
were 5.8, 0.78 logMAR, and 199.9±60.9µ, respectively. Comparison of  post-injection results of  IVB and IVR treatments did not reveal 
a statistically significant difference. Mean injection rates per patient while receiving IVB and IVR treatments were 0.46/month and 0.44/
month, respectively (p>0.05). 
Conclusions: This study shows that the improvement in AS, CFT, and VA, achieved with the PRN IVB treatment, seems to be main-
tained after switching to IVR. 
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Materials and Methods
The study followed the tenets of  the Declaration of  Helsinki and 
had the approval of  the Institutional Research Board. Written in-
formed consent was obtained from each participant.
The medical records of   patients with neovascular ARMD, who 
first underwent treatment with Pro Re Nata (PRN) IVB and later 
with PRN IVR, were reviewed retrospectively from May 2006 to 
June 2009 at the Ophthalmology Department of  the Medical Fac-
ulty of  Gazi University.
At the beginning of  the study, a month after the last IVB treat-
ment, and a month after the transition to IVR treatment, best-
corrected visual acuity (BCVA, logMAR), applanation tonometry, 
slit-lamp evaluation, dilated biomicroscopic fundus examination, 
fundus fluorescein angiography (FFA), and central foveal thick-
ness (CFT) measurement using optical coherence tomography 
(OCT, Humphrey model 3000 (Zeiss-Humphrey Instruments, 
San Leandro, CA)) were performed.
Re-treatment criteria were defined based on an activity scoring 
system, including 5 parameters (Table 1), which was developed 
at our clinic. 
1. OCT: After pupil dilatation, six consecutive 6-mm-long scans 
containing 128 axial profiles (A-scans) at equally spaced an-
gular orientations in a radial spoke pattern centered on the 
fovea (known as Fast Macular Thickness Protocol) were ob-
tained for each eye. Using Retinal Thickness Mapping Soft-
ware, the mean retinal thickness value, which was measured 
in the central disc with a diameter of  1000µm in the center 
of  the macula, was used as central foveal thickness (CFT). 
The fluid pattern (subretinal / intraretinal diffuse / cystoid / 
pigment epithelial detachment - PED) was also noted. Only 
CFT was used as an activity parameter in AS, and a change in 
this by at least 10% in the negative or positive direction was 
considered a significant decrease or increase. The amount of  
fluid at the beginning was scored as “2”. It was scored as “0” 
if  there had been no fluid, “1” if  there had been a decrease, 
and “3” if  there had been an increase (in CFT).
2. Amount of  hemorrhage: The amount of  hemorrhage asso-
ciated with the lesion (in ophthalmoscopy, colored fundus 
photography or FA) was noted, and if  there had been any 
at the beginning, it was scored as “2”. If  there had been no 
hemorrhage it was scored as “0”. If  hemorrhage had de-
creased it was scored as “1”, if  it had remained the same it 
was scored as “2”, and if  it had increased it was scored as 
“3”.
3. FA staining pattern: No staining or window defect (0), stain-
ing of  scar tissue or PED (1) and late leakage (2) were noted. 
4. The area of  the lesion (mm2): This was measured in FA and 
the baseline area (or no change) was scored as “1”, an in-
crease by at least 10% (of  the original area) as “2” and a 
decrease by at least 10% as “0”.
5. Visual assessment: Objective visual acuity was measured and 
noted as a baseline and scored as “1”. If  there had been a 
decrease in vision (any line loss) it was scored as “2”, and any 
increase in vision (any line gain) scored as “0”. The patient 
was also enquired regarding how he felt about any change in 
his vision, noted as subjective vision, which was scored as 
“0” if  he felt better, “2” if  he felt worse, and “1” if  he did 
not feel any change (baseline).
At the end of  the assessment, the numbers obtained were summed 
and an activity score was calculated for each lesion at each visit. 
AS results and the number of  injections before and after switch-
ing the treatment to IVR were compared.
All intravitreal injections were made using a standard protocol 
and established guidelines. Following topical anesthesia with 
proparacaine, the eyelids and eyelashes were scrubbed with pov-
idone-iodine (10%). After placement of  the sterile lid speculum, 
Table 1. Clinical Activity Scoring System
Parameter Grading Score
Hemorrhage: Amount of  hemorrhage associated with the lesion No hemorrhage
Decreased
Beginning/same amount
Increased
0
1
2
3
OCT: Subretinal fluid/retinal thickening/PED None
Decreased
Any amount at beginning/Stable
Increased
0
1
2
3
FA: Staining pattern NO staining/window defect
Staining of  scar tissue/PED
Late leakage
0
1
2
Size of  the lesion: Lesion area in FA Decreased
Beginning Size/Stable
Increased
0
1
2
Visual assessment: Objective Increased
No change
Decreased
0
1
2
Visual assessment: Subjective Increased
No change
Decreased
0
1
2
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povidone-iodine (5%) drops were applied over the ocular surface. 
Using a sterile 1-ml tuberculin syringe with a 30-gauge needle, ei-
ther 1.25 mg/0.05 ml bevacizumab or 0.5 mg/0.05 ml ranibizum-
ab was injected into the vitreous cavity through the pars plana, 
approximately 3-4 mm posterior to the superotemporal limbus. A 
topical fluoroquinolone antibiotic was used thrice a day for five 
days after the injection.
Power analysis was performed to justify the number of  patients 
enrolled in the study. Data were statistically analyzed using SPSS 
16.0 software. The Paired Samples t-test was used to compare 
IVB and IVR treatments. Statistical significance was defined as 
p<0.05. 
Results
32 eyes of  31 patients (12 women and 19 men) with neovascu-
lar ARMD were included in the study. The mean age of  the pa-
tients was 73.2 ± 10.2.  The mean follow-up period was 12.3 ± 
4.7 months, and the mean duration of  IVB treatment 8.1 ± 3.1 
months, followed by 4.2 ± 1.6 months of  IVR treatment. 
At the beginning of  the study, the mean AS was 8.9, VA: 0.99 
logMAR, and CFT: 312.7 ± 81.1. A month after the last IVB in-
jection, AS became 5.1 (p = 0.031), VA: 0.69 logMAR (p = 0.029), 
and CFT: 210.4 ± 80.4µ (p = 0.028). A month after the last IVR 
injection, AS was 5.8, VA was 0.78 logMAR, and CFT was 199.92 
± 60.9µ. (Figure 1-2-3)
Comparison of  post-injection results of  IVB and IVR treatments 
did not reveal any statistically significant difference. Mean injec-
tion rates per patient while receiving IVB and IVR treatments 
VA (logMAR)
Pre-treatment
1 mo after IVB
1 mo after IVR
Figure 2. Changes in CFT over the treatment period.
Figure 1. Changes in VA over the treatment period.
Figure 3. Changes in CFT over the treatment period.
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were 0.46/month and 0.44/month, respectively (p=0.098). 
AS, VA and  CFT results were compared after IVB and IVR treat-
ments and no statistically significant differences were determined 
(p = 0.135, p = 0.097, and p = 0.118, respectively).
No major ocular side-effects, such as endophthalmitis or retinal 
detachment, were noted. In addition, there were no cases of  ad-
verse systemic events, such as myocardial or cerebral infarction, 
or treatment-emerged hypertension; and no patient died during 
the follow-up period.
Discussion
Currently, many clinicians are puzzled by the scientific challenges 
and economic problems associated with these drugs. Numerous 
retrospective and prospective studies continue to question the 
outcomes of  eye treatments using IVB and IVR.
Both ranibizumab and bevacizumab bind VEGF at the same po-
sition; however, they differ in their size, affinity for VEGF, speed 
of  clearance from the eye, and cost.[7]
One of  the pharmaceutical industry-independent head-to-head 
randomized controlled studies, A Comparison of  AMD Treat-
ment Trials: Ranibizumab-Bevacizumab Trial (CATT), reported 
results for a year in May 2011 and for two years in July 2012.[8,9] 
At the end of  one and two years bevacizumab and ranibizumab 
were found to have had similar effects on visual acuity, with the 
dosing regimen being the same. Both drugs reduced retinal and 
subretinal fluid effectively. The CATT results support the contin-
ued and widespread use of  IVB as an effective, low-cost alterna-
tive to IVR.
A similar study entitled A Randomized Controlled Trial of  Al-
ternative Treatments to Inhibit VEGF in Age-Related Choroidal 
Neovascularization (IVAN) reported results for a year in July 2012 
and concluded that both drugs had equivalent effects on visual 
function.[10] Ranibizumab, and monthly treatment, resulted in 
significantly better morphologic outcomes.
The first study on treatment switching  evaluated patients who 
had at least three IVB treatments before switching to IVR treat-
ment, and concluded that there were no apparent differences in 
visual acuity outcomes or injection rates.[1] The investigators of  
the study found the average injection rate for the two drugs to be 
0.66/month. In our study, mean injection rates per patient while 
receiving IVB and IVR treatments were 0.46/month and 0.44/
month, respectively; and this difference was also not statistically 
significant.
Another study similar to ours compared patients who had been 
treated three times or more with IVB every 6 weeks initially, and 
then as needed before being switched to IVR every 4 weeks until 
they were clinically stable; the IVR treatment was continued on an 
"as needed” basis.[11] The results revealed significant improve-
ments in VA and CFT in patients who had been initially treated 
with IVB. Besides, a further significant improvement in VA and 
reduction in CFT were seen in these patients after they had been 
switched to IVR. Both the studies are similar in respect of  ab-
sence of  i) patient or physician preference, ii) lack of  response to 
one of  the medications and iii) Inability on the part of  patients 
to pay. This allowed for patients to be used as their own controls, 
avoiding physician selection bias. 
Another treatment switching study showed that switching from 
bevacizumab to ranibizumab results in a transient decrease of  
visual acuity and an increase of  retinal thickness, causing a tran-
sient “instability” in the eye.[12] The final visual acuity and retinal 
thickness after IVR were better than those after IVB in their study.
A major difference between our study and those of  Kent et al 
and Karagiannis et al, is in the treatment frequency. The former 
started with a monthly treatment regimen and then switched to 
an “as-needed regimen”, while the latter compared only monthly 
regimens. We compared PRNs protocol for IVB and IVR treat-
ments. 
There are reports in the scientific literature that provide no evi-
dence of  either of  these drugs being superior to the other. In all 
these reports, separate patient groups, treated only with IVB or 
IVR, were compared.
Landa et al, Gamulescu et al and Fong et al reported that there is 
no significant difference in the efficacies of  IVB and IVR.[13-15]
Subramanian et al reported outcomes for a year for a prospective 
study that failed to show any difference in visual and anatomic re-
sults between the two treatments. But, patients in the IVB group 
received a statistically significant greater number of  injections 
than those in the IVR group.[16] These investigators suggested 
that a possible reason for this may have been a tachyphylactic re-
sponse due to different treatment doses for the two drugs. But, 
according to Schmucker et al,  the bevacizumab molecule is about 
three times as large as ranibizumab and may remain in the eye 
longer, allowing for less frequent injections.[17]
Biswas et al compared IVB with IVR head-to-head as two groups.
[18] The changes in the means of  BCVA and CFT  were com-
pared and they concluded that IVB and IVR are equally safe and 
effective when administered monthly as injections thrice and then 
as needed. The mean number of  injections required in their study 
in the IVB group (4.3) was less than the number required in the 
IVR group (5.6). 
On the other hand, Chang et al reported a significantly better 
short-term effectiveness with IVR than IVB as measured by OCT.
[19] We suggest that the present study is unique as it allows for 
comparisons to be made between two different drugs on the basis 
of  responses elicited by them from the same patient. Besides, re-
treatment decisions were based on objective criteria, supported 
by a clinical activity scoring system. In many studies, the chief  
criteria on which decisions to treat or re-treat ARMD are based 
are fluorescein leakage, the angiographic appearance of  the lesion 
and OCT. However, the concordance between OCT and FA is 
not always a reliable indicator [20], and other parameters may have 
to be considered to decide on the need for re-treatment. Some of  
these parameters may be i) presence of  subretinal hemorrhage as-
sociated with the lesion, ii) change in the size of  the lesion and iii) 
visual acuity. Most clinicians rely on their experience and intuition 
to decide on new treatments using some of  these parameters. AS 
is particularly desirable in standardizing re-treatment protocols as 
it is important not to over-treat eyes in order to avoid injection- 
and drug-related complications as well as the high costs of  the 
treatment.  
The main limitations of  this study are its retrospective nature and 
a relatively small sample size; therefore, to provide a clear and 
reliable answer to the question of  whether bevacizumab or ra-
nibizumab is the better drug, prospective and randomized trials 
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are needed. In addition, AS  may be modified by the use of  other 
tools like central field acuity perimetry for visual assesment to be 
more objective.
In conclusion, this study shows that improvements in AS, CFT, 
and VA, achieved with the PRN IVB treatment, seems to be main-
tained after switching to IVR. Further, it also reveals that there is 
no significant difference in injection rates between the treatments.
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